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riglyceride-Rich Lipoprotein
emnant Levels and Metabolism
ime to Adopt These
rphan Risk Factors?*
liot A. Brinton, MD,
. Nazeem Nanjee, PHD,
aul N. Hopkins, MD, MSPH
alt Lake City, Utah
mong the major components of the standard plasma lipid
rofile, the total triglyceride (TG) level is generally consid-
red the weakest risk factor for atherosclerosis, for which
here are several likely contributing reasons. First, TG is
eadily metabolized and is not a major constituent of
therosclerotic plaque. Second, plasma TG varies greatly
rom day to day in the fasting state and even more in the
enerally unmeasured postprandial state. More importantly,
here is considerable heterogeneity among TG-rich lipopro-
eins (TGRLs) ranging from highly atherogenic TGRL
emnants to larger chylomicrons (and larger very low-
ensity lipoproteins, VLDLs) too large to penetrate the
rtery wall (1) and hence ineffectual substrates for plaque
rogression (2). The preferential excess of these very large,
onatherogenic TGRLs above a plasma TG of approxi-
See pages 2219 and 2225
ately 600 to 800 mg/dl (3) paradoxically results in generally
ow (4), albeit not always absent (5), atherosclerosis risk at the
ighest TG levels. Thus, TG contrasts sharply with choles-
erol, with its limited metabolism, well-established involve-
ent in atherogenesis, and relative constancy in plasma level,
uch that risk even from somewhat heterogeneous low-density
ipoprotein (LDL) particles is a strong log-linear function (6).
espite these differences, however, total TG levels are impor-
ant because the TGRLs that carry the majority of plasma TG
arry more cholesterol molecules per particle than does LDL.
lasma TG levels, therefore, predict atherosclerosis because
hey are an indirect measure of the cholesterol content of
otentially atherogenic TGRLs.
Lipolysis of TG in nascent TGRLs converts them to
remnant” lipoproteins, and atherosclerosis risk correlates
oth with remnant levels and metabolism. Each of these
wo parameters is highlighted by two reports in this issue of
he Journal (7,8). First, TGRL remnant levels carry a strong
isk because they have elevated cholesterol content and
xtended plasma residence time, and thus greater atheroge-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Genetics, University of Utah School oftedicine, Salt Lake City, Utah.icity compared with their precursors. This effect is most
lear in type III dyslipidemia, with greatly reduced remnant
emoval rates causing severely increased remnant levels and
triking coronary artery disease (CAD) risk (9). Less dra-
atically elevated remnant levels strongly predict prevalent
therosclerosis in patients with (10) and without diabetes
ellitus (11). The report of Fukushima et al. (7) in this issue
f the Journal adds to this literature by showing that TGRL
emnant levels predict CAD cross-sectionally and prospec-
ively in diabetes.
There are several methods for estimating plasma levels of
GRL remnants. Classically, in the ultracentrifugal density
1.006 g/ml fraction either a cholesterol mass 0.3 times
otal plasma TG (cholesterol-rich VLDL by beta quantifi-
ation) or the presence of a broadened band of beta mobility
n agarose gel electrophoresis (beta-VLDL) signals excess
emnant levels (9). These assays, however, are generally
vailable only in lipid reference laboratories. Another
ethod, suggested in the National Cholesterol Education
rogram-Adult Treatment Panel III guidelines (12) to
apture risk associated with remnants, is the calculation of
on–high density lipoprotein (HDL) cholesterol. This
imply lumps cholesterol content of remnants together with
hat of all other particles besides HDL (12) and is to be used
n place of LDL-cholesterol when the plasma TG exceeds
00 mg/dl. One obvious drawback of non–HDL-
holesterol measurement is that it cannot distinguish the
road variability of atherogenicity among the many non-
DL particles. Non–HDL-cholesterol is particularly mis-
eading when excess (nonatherogenic) chylomicrons carry
lasma TG over approximately 1,000 mg/dl.
Recently, a convenient immunologic method purported
o isolate remnants has been developed. High-density li-
oprotein and nascent chylomicrons are removed using
mmobilized antibodies against apolipoprotein (apo) A-I.
ost LDLs and VLDLs are then removed using a mono-
lonal antibody directed against a middle epitope of apo
-100. Chylomicron remnants (with apo B-48 but without
he apo B-100 epitope) and some VLDL enriched in apo E
emain unbound, constituting “remnant-like particles”
RLP), and their cholesterol content is measured as
RLP-C ”(13). The mechanism(s) by which these apo-B-
00–containing VLDLs (and some LDLs) fail to bind to
he anti-apo B-100 monoclonal antibodies is unknown. The
eterogeneity among RLPs is great and varies with patient
henotype (14). Remnant-like particle-cholesterol may not
lways add to risk information available from plasma TG
ecause the two generally are highly correlated (15,16).
evertheless, the RLP fraction appears enriched in true
GRL remnants (17) and can be positively associated with
AD risk independent of plasma TG (18). Although RLPs
re of diverse origins and composition, RLP-C correlates
trongly with the related lipid parameter of VLDL-cholesterol
lus intermediate-density lipoprotein-cholesterol by ultracen-
rifugation or native gradient gel electrophoresis (19) and does
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Editorial Comment June 16, 2004:2233–5ot correlate with unrelated parameters such as LDL-
holesterol or LDL apo B (11). Remnant-like particle-
holesterol levels are elevated in most states of increased
therosclerosis risk, being higher in men than in women
11), in older than in younger subjects (11), in postmeno-
ausal than in premenopausal subjects (11), postprandially
11), in obesity (20), in impaired glucose tolerance (21), in
iabetes mellitus (22), and in end-stage renal disease and
emodialysis (11,22). More importantly, RLP-C is also
levated in atherosclerosis, as defined by carotid intima-
edia thickness (18) and by coronary angiography and
linical criteria (11,19). Most recently, Fukushima et al. (7)
n this issue of the Journal report higher RLP-C in diabetics
ith CAD at baseline and in prospective follow-up, appar-
ntly independent of other standard risk factors, including
otal TG.
Remnants may be atherogenic by enhancing macrophage
ipid content, inducing platelet aggregation, impairing
ndothelium-dependent coronary vasodilation, and activat-
ng endothelial adhesion molecule expression (11). Treat-
ent with HMG-CoA reductase inhibitors (“statins”) low-
rs RLP-C levels (23), thus possibly constituting one of
heir anti-atherosclerotic mechanisms.
Triglyceride-rich lipoprotein lipolysis produces remnants
nd remnant uptake eliminates them. These two processes
egulate remnant levels and thereby contribute importantly
o atherosclerosis risk. In addition, remnant production and
emoval may have other effects on atherogenesis. In contrast
o the considerable data linking TGRL remnant levels with
therosclerosis, the relationship between remnant metabo-
ism and atherosclerosis is much less clear. For example,
evere hypertriglyceridemia due to severely impaired lipol-
sis from complete deficiency of lipoprotein lipase (LPL)
robably does not increase CAD risk (4). In contrast,
eterozygous LPL deficiency, frequently associated with
oderately increased TG as well as modest reductions in
DL-cholesterol, may increase CAD risk (5). Further, a
ommon LPL gene variant with increased lipolytic activity
s associated with lower CAD risk (24).
Despite the importance of LPL activity, many other factors
uch as particle content of apos C-I, C-II, and C-III help
egulate TGRL lipolysis (25), the overall rate of which might
e a better CAD risk predictor. In this issue of the Journal,
posito et al. (8) measured TG lipolysis in vivo by the turnover
f an artificial chylomicronlike emulsion, radiolabeled both in
he TG and cholesteryl-ester (CE) moieties, which appears to
eflect metabolism of native chylomicrons. The disappearance,
r fractional catabolic rate (FCR), of the TG component is a
unction both of lipolysis and of remnant particle removal,
hereas the disappearance of the CE label is only a function of
oloparticle clearance. Thus, one can estimate the rate of
lasma TG removal by lipolysis by comparing the FCR of CE
o that of TG. The expression 1  (CE FCR)/(TG FCR) is
alled the delipidation index (DI) (26) because it estimates in
ivo lipolysis by correcting total TG disappearance (TG FCR)
or its loss through remnant particle uptake (CE FCR). lSposito et al. (8) studied 63 diabetic subjects with and 35
ithout angiographically proven CAD at baseline and then
ollowed the former group for about four years with aggressive
ntianginal and statin therapies (LDL-cholesterol goal 100
g/dl). The TG FCR, CE FCR, and DI were all reduced
imilarly in CAD subjects at baseline. For the first time, the
bility of these parameters to predict future CAD was tested,
nd surprisingly, CE FCR (remnant holoparticle clearance)
redicted neither angiographic nor clinical progression of
AD. Lipolysis (DI), however, strongly predicted both, even
fter inclusion of other standard risk factors in multivariate
nalysis. This suggests that reduced TGRL lipolysis might be
ore proatherogenic than reduced remnant clearance, despite
he fact that TGRL lipolysis would be expected to reduce
emnant levels whereas reduced remnant clearance would be
xpected to increase them. Given the aggressive treatment
uring follow-up, however, the lack of relationship between
aseline CE FCR and CAD progression might simply be an
rtifact of statin-induced reductions in remnant levels. Unfor-
unately, we do not know if remnant levels are reduced in
ow-DI subjects (with or without CAD progression) because
hey were not measured in this or any other DI study of which
e are aware.
If low lipolysis (DI) reduces remnant levels, how might it
ncrease CAD progression? First and second, as it raises
lasma TG levels (especially postprandially), it should
mpair arterial vasodilator capacity (27) and enhance proco-
gulant factors (28). Interestingly, TG levels reportedly
redict CAD in statin-treated patients (29). Third, reduced
ipolysis decreases generation of free fatty acids, which are
atural activator ligands to alpha subclass peroxisome pro-
iferator activated receptors (PPARs). This decreased
PARs activity should increase endothelial production of
roinflammatory tumor necrosis factor-alpha and vascular
ell adhesion molecule-1 (30). Fourth, because remnants
ust reach a certain degree of lipolysis to be recognized by
emnant uptake receptors, reduced lipolysis and resulting
ncreased plasma residence time would enhance TGRL
vailability for neutral-lipid exchange with LDL and HDL.
ot only may the resulting decreases in LDL and HDL
article size promote atherosclerosis, but the clearance rate
f HDL would be enhanced and its plasma levels decreased.
urthermore, excess CE enrichment of TGRL remnants
ould be proatherogenic, especially if the remnants were
mall enough to enter the arterial wall (31) and be taken up
y the macrophage apo B-48 receptor (32). Unfortunately,
etailed lipoprotein characterization to verify these expected
ompositional changes in remnants, LDL, and HDL has
ot been performed in any study of remnant metabolism of
hich we are aware.
In conclusion, RLP-C levels are a promising risk factor for
hich a practical and reproducible method of measurement is
ow available. Further studies are required to establish RLP-C
evels as a clinically useful tool for diagnosis and follow-up of
therosclerosis risk. Randomized prospective trials of lipid-
owering treatment with reductions in clinical CAD events
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June 16, 2004:2233–5 Editorial Commentredicted by reductions in RLP-C levels independent of other
isk factors would be particularly convincing. In contrast, the
ssessment of TGRL lipolysis (as well as LPL activity) is
mpractical even for large clinical trials, more so for routine
linical use. Nevertheless, the study of Sposito et al. (8) and
nother such report (33) have provided valuable insight into
he likely contribution of TGRL lipolysis to CAD risk. Ideally,
feasible clinical assay of some parameter strongly correlated
ith TGRL lipolysis rates will be developed, perhaps either
ssessment of TG clearance by post-challenge TG level (or
rea under the curve) during a fat tolerance test or the
easurement of some particular lipoprotein subfraction.
riglyceride-rich lipoprotein lipolysis can be increased by
brates and thiazoledinediones by different and perhaps com-
lementary mechanisms (34), although this effect does not yet
onstitute a clinical indication for use of these agents.
The TGRL lipolysis rates and plasma levels of its resulting
emnants appear to be important factors in atherosclerosis risk,
nd thus are potentially important targets in atheroprevention.
hese parameters are not yet, however, clinically useful tools
or diagnosis and prevention of atherosclerosis.
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